Fed. Circ. OKs Ruling Barring Generic Lyrica Until 2018

Law360, Los Angeles (February 6, 2014, 4:48 PM EST) -- Pfizer Inc. on Thursday won a ruling from the Federal Circuit upholding a lower court's decision blocking a slew of generic-drug makers, including Teva Pharmaceuticals USA Inc. and Actavis Inc., from selling generic versions of its popular nerve pain drug Lyrica until the patent for the drug expires in 2018.

A three-judge panel affirmed U.S. District Gregory M. Sleet's findings that the generics makers had infringed Pfizer's U.S. Patent number 6,197,819 and that the patent is not invalid for obviousness, lack of enablement or insufficient written...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.